ImmuDyne: Second Patent Issued for Topical Treatment of Hair Loss/Alopecia; Q1 Launch Scheduled
MT. KISCO, N.Y., Jan. 24, 2017 (GLOBE NEWSWIRE) -- ImmuDyne (OTCQB:IMMD), a leader in the development and marketing of OTC health and wellness products addressing large unmet needs, today announced the issuance of a 2nd Patent relating to the topical treatment of hair loss/alopecia. The invention also provides methods for use:
In September 2016, Immudyne reached a definitive agreement with Pilaris Laboratories, LLC (“Pilaris”), for a sole and exclusive worldwide license to commercialize the patented PilarisMax line of hair loss products. Pilaris was founded by two prominent dermatologists, Steven D. Shapiro M.D. and Michael T. Borenstein M.D. Ph.D. after 5 years of clinical research on topical dihydrotestosterone (DHT) inhibitors. Dr. Shapiro has over 20 years of clinical experience with treating hair loss and hair transplant procedures. Dr. Borenstein holds a Ph.D. in Pharmacology and has a background in scientific research in addition to over 12 years of clinical dermatology practice.
Branding is now completed, and the products will now launch under the Shapiro M.D. label. Steven Shapiro M.D. stated, “We are very impressed with the work put in by ImmuDyne. Our collective goal is to become a leading brand in the men’s and women’s hair loss category.”
The official launch date of Shapiro M.D. should occur in Q1 and will be announced soon.
lmmuDyne, Inc. (the "Company") is a health and wellness company which develops, manufactures, markets, and sells innovative lifestyle products. The Company's lead products contain its proprietary yeast beta glucans that have been shown through testing and analysis to support the immune system. The Company's products include once a day oral intake capsules as well as topical serums and creams for skin application. lmmuDyne also has developed a proprietary natural delivery technology for potential new market opportunities. All of lmmuDyne's intellectual property is protected by patents and/or trade secrets. Additional information can be found on the web at www.immudyne.com.
Cautionary language regarding Forward-Looking Statements Safe Harbor Act Disclaimer: Forward looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Certain statements in this press release, including projections with respect to lmmuDyne's results of operations, may contain words such as "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "projects," "plans," "targets" and other similar language and are considered forward-looking statements. These statements are based on management's current expectations, estimates, and forecasts. These forward-looking statements are subject to important assumptions, risks and uncertainties, which are difficult to predict and therefore the actual results may be materially different from those discussed.
Contact: lmmuDyne, Inc. Mark McLaughlin: +1-914-714-8901Source: ImmuDyne, Inc.
Released January 24, 2017